Ayala Pharmaceuticals, Inc.
1007 North Orange Street
4th Floor
Wilmington, DE 19802
United States
857-444-0553
https://www.ayalapharma.com
版塊: Healthcare
行業: Biotechnology
全職員工:
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Ruth Ben Yakar Ph.D. | Chief Exec. Officer | 無 | 無 | 1970 |
| Dr. Stela Gangrenovitch Ph.D. | Co-Founder, Chief Scientist Officer and Director | 無 | 無 | 無 |
| Mr. Mark Gengrinovitch LLB | Co-Founder, Chief Financial Officer and Director | 無 | 無 | 無 |
截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
公司管治
截至 無 止，Ayala Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
